Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.60 |
| ▸ | SRC | P12931 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19350822 | 0.97 | FGFR1 (0.61) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL30419173 | 0.97 | FGFR1 (0.61) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20603995 | 0.87 | FGFR1 (0.55) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20627054 | 0.87 | FGFR1 (0.57) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20627062 | 0.84 | FGFR1 (0.54) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20603931 | 0.84 | FGFR1 (0.56) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20603933 | 0.84 | FGFR1 (0.56) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20627063 | 0.81 | FGFR1 (0.55) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19350832 | 0.80 | FGFR1 (0.55) | FGFR1SRCMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3019071 | 0.78 | RAB9A (0.56) | MAPTALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071523-A | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2018-12-21 | — | — | CN | claimed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| CN-109071523-B | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| EP-3424924-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-3424924-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| CN-109071523-A | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017152874-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FLT3, WEE1, SLC14A1 | FGFR1 294/4885SRC 24/4885MAPT 2368/4885 |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | FLT3, WEE1, SLC14A1 | FGFR1 294/4885SRC 24/4885MAPT 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.